Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults
06 Mars 2024 - 5:45PM
Business Wire
Cellvizio Food Intolerance Test (C-FIT)
delivers real-time, in vivo visibility to accurately identify food
intolerance in patients suffering from Irritable Bowel Syndrome
(IBS)
Metrodora will serve as Center of Excellence
for patient care and physician training to enable broad access to
this breakthrough procedure
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of
Cellvizio®, the multidisciplinary probe and needle-based confocal
laser endomicroscopy (p/nCLE) platform, and Metrodora Institute, a
leading multispecialty healthcare institute, today announced the
formation of a new partnership. This collaboration aims to
establish Metrodora Institute as the first U.S. Center of
Excellence that will serve as the model of patient care and
physician training on the use of Cellvizio for identifying and
treating food intolerances in patients suffering from Irritable
Bowel Syndrome (IBS). The Cellvizio Food Intolerance Test (C-FIT)
offers a groundbreaking approach to diagnosing food intolerances,
providing a real-time visualization of the intestinal barrier
during a food challenge.
In the United States, about 10-15%1 of the general adult
population suffers from IBS, a condition reportedly linked to
atypical food intolerance in the majority of cases, characterized
by a group of symptoms including abdominal pain, bloating, and
changes in bowel habits (diarrhea, constipation, or both). This
condition significantly affects the quality of life of those
affected who often face a protracted and distressing journey of
medical consultation that could last 2 to 3 years on average with
no guaranteed path to identifying the underlying cause of their
symptoms.
"This partnership is perfectly aligned with our strategic
ambition and represents a significant step forward in expanding the
use of Cellvizio in the food intolerance markets. The Cellvizio
U.S. Center of Excellence at the Metrodora Institute serves as a
key driver in increasing awareness among the medical and patient
communities about C-FIT, positioning it as a benchmark method for
food intolerance detection", said Sacha Loiseau, Ph.D., Founder,
Chairman and Chief Executive Officer of Mauna Kea Technologies.
"There is an urgent, unmet need for the immense pool of IBS
patients who endure debilitating daily complications. It is crucial
to swiftly extend the C-FIT procedure to as broad an audience as
possible."
Metrodora was established in 2021 as a multidisciplinary care
and research center for people with neuroimmune disorders,
including neurogastrointestinal disorders. Metrodora’s
state-of-the-art ambulatory surgery center in Salt Lake City, Utah,
offers advanced diagnostic and therapeutic procedures to evaluate
and treat a range of complex and routine conditions.
“We couldn’t be more excited about being named the first U.S.
Center of Excellence for implementing and serving as a healthcare
model for the C-FIT procedure,” said John Wirthlin, CEO,
Metrodora Institute. “Many patients live with undiagnosed food
intolerances, simply because existing testing methods cannot
identify the underlying issues. Our vision is that Metrodora
Institute will adopt novel technologies like Cellvizio to improve
the lives of the patients we serve.”
***
About Mauna Kea Technologies Mauna Kea Technologies is a
global medical device company that manufactures and sells
Cellvizio®, the real-time in vivo cellular imaging platform. This
technology uniquely delivers in vivo cellular visualization which
enables physicians to monitor the progression of disease over time,
assess point-in-time reactions as they happen in real time,
classify indeterminate areas of concern, and guide surgical
interventions. The Cellvizio® platform is used globally across a
wide range of medical specialties and is making a transformative
change in the way physicians diagnose and treat patients. For more
information, visit www.maunakeatech.com.
About Metrodora Institute Located in Salt Lake City,
Utah, the Metrodora Institute was founded in 2021 with the vision
of reimagining care for patients with complex multisystem
disorders. Metrodora is uniquely positioned to advance the latest
clinical care and develop and commercialize new diagnostic tests
and therapeutics for patients living with these often-debilitating
conditions. Metrodora Institute has created an innovative offering
with a collaborative multidisciplinary approach to medicine.
Metrodora currently treats neurological, gastrointestinal,
immunological, autoimmune, pain and metabolic disorders.
Disclaimer This press release contains forward-looking
statements about Mauna Kea Technologies and its business. All
statements other than statements of historical fact included in
this press release, including, but not limited to, statements
regarding Mauna Kea Techonologies' financial condition, business,
strategies, plans and objectives for future operations are
forward-looking statements. Mauna Kea Technologies believes that
these forward-looking statements are based on reasonable
assumptions. However, no assurance can be given that the
expectations expressed in these forward-looking statements will be
achieved. These forward-looking statements are subject to numerous
risks and uncertainties, including those described in Chapter 3 of
Mauna Kea Technologies' 2022 Universal Registration Document filed
with the Autorité des marchés financiers (AMF) on June 28, 2023
under number D-23-0545, which is available on the Company's website
(www.maunakeatech.fr), as well as the risks associated with changes
in economic conditions, financial markets and the markets in which
Mauna Kea Technologies operates. The forward-looking statements
contained in this press release are also subject to risks that are
unknown to Mauna Kea Technologies or that Mauna Kea Technologies
does not currently consider material. The occurrence of some or all
of these risks could cause the actual results, financial condition,
performance or achievements of Mauna Kea Technologies to differ
materially from those expressed in the forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or subscribe for, or the solicitation
of an order to buy or subscribe for, shares of Mauna Kea
Technologies in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. The
distribution of this press release may be restricted in certain
jurisdictions by local law. Persons into whose possession this
document comes are required to comply with all local regulations
applicable to this document.
1 Hungin APS, Tack J, Mearin F, Whorwell PJ, Dennis E, Barghoui
V. Irritable bowel syndrome (IBS): prevalence and impact in the USA
– the truth about IBS (T-IBS) survey. Am J Gastroenterol. 2002;
97:242. (Poster #460)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240306830425/en/
Mauna Kea Technologies investors@maunakeatech.com
NewCap - Investor Relations Aurélie Manavarere / Thomas
Grojean +33 (0)1 44 71 94 94 maunakea@newcap.eu
Mauna Kea Technologies (EU:ALMKT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Mauna Kea Technologies (EU:ALMKT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024